Edwards Lifesciences’ Solo Act Shines In 2001, MDDI Index Edges Ahead 4%
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences' ability to leverage a growing interventional cardiology market and its leadership in tissue replacement heart valves helped the Baxter spin-off capture Wall Street's attention in 2001, the firm's first full year as a stand-alone entity. The company's stock price jumped 56% as a result